PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32301059-6	2020	Ticagrelor treatment also reversed the increases in the resting level of free Ca2+ and mRNA level of P2Y12 receptors as well as preserved ER stress and apoptosis in insulin-resistant H9c2 cells.	Ticagrelor	0-10	purinergic receptor P2Y12	Rattus norvegicus	101-106	
30721704-1	2019	Ticagrelor is a direct acting and reversibly binding P2Y12 antagonist approved for the prevention of thromboembolic events.	Ticagrelor	0-10	purinergic receptor P2Y12	Rattus norvegicus	53-58	
22546677-1	2012	Ticagrelor (1) is the first reversible P2Y12 receptor antagonist blocking adenine diphosphate (ADP)-induced platelet aggregation with rapid onset and offset of effects.	Ticagrelor	0-10	purinergic receptor P2Y12	Rattus norvegicus	39-44	
29367102-9	2018	In contrast, the same concentration of ticagrelor, another P2Y12 inhibitor did not induce fibrillation events though it decreased the contractility of ventricular myocytes significantly.	Ticagrelor	39-49	purinergic receptor P2Y12	Rattus norvegicus	59-64	
24643079-2	2014	Clinical data show that ticagrelor, a direct-acting, reversibly binding P2Y12-receptor antagonist, reduces total cardiovascular events, including stroke.	Ticagrelor	24-34	purinergic receptor P2Y12	Rattus norvegicus	72-77	
24643079-10	2014	Our results show that ticagrelor is protective against ischemia-induced cerebral injury and this effect is mediated, at least partly, by inhibition of P2Y12-mediated microglia activation and chemotaxis.	Ticagrelor	22-32	purinergic receptor P2Y12	Rattus norvegicus	151-156	
29992382-6	2018	Ticagrelor, a P2Y12 antagonist, and VX-765 decreased infarct size to 42.8 +- 3.3 and 29.2 +- 4.9%, respectively.	Ticagrelor	0-10	purinergic receptor P2Y12	Rattus norvegicus	14-19	
19846210-0	2010	The novel P2Y 12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats.	Ticagrelor	28-35	purinergic receptor P2Y12	Rattus norvegicus	10-16	
22071958-2	2011	Both irreversibly (clopidogrel) and reversibly binding (ticagrelor, AZD6140) P2Y12 antagonists are clinically used for restricted periods, but possible differences in platelet function recovery after drug cessation have not been investigated.	Ticagrelor	56-66	purinergic receptor P2Y12	Rattus norvegicus	77-82	
22071958-2	2011	Both irreversibly (clopidogrel) and reversibly binding (ticagrelor, AZD6140) P2Y12 antagonists are clinically used for restricted periods, but possible differences in platelet function recovery after drug cessation have not been investigated.	Ticagrelor	68-75	purinergic receptor P2Y12	Rattus norvegicus	77-82	
33563204-13	2022	CONCLUSION: Our results suggest that the P2Y12 inhibitor, ticagrelor may have a therapeutic potential in reducing the progression of PF.	Ticagrelor	58-68	purinergic receptor P2Y12	Rattus norvegicus	41-46	
34748820-15	2021	Compared to clopidogrel, prasugrel and ticagrelor are potent P2Y12 inverse agonists with superior antiplatelet and antithrombotic efficacy in experimental sepsis.	Ticagrelor	39-49	purinergic receptor P2Y12	Rattus norvegicus	61-66	
35595877-15	2022	The P2Y12 inhibitor ticagrelor per se induces a humoral cardioprotective signal.	Ticagrelor	20-30	purinergic receptor P2Y12	Rattus norvegicus	4-9	
32832010-2	2020	Here, we investigate whether direct NLRP3 inflammasome inhibition exerts additive effects on myocardial protection induced by the P2Y12 receptor antagonist Ticagrelor.	Ticagrelor	156-166	purinergic receptor P2Y12	Rattus norvegicus	130-135